Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.
Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.
These notes describe the products in the RTSM / IRT guide.
Endpoint Clinical RTSM
Best for
Sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows
What to consider
Endpoint Clinical is an RTSM specialist with two platforms: PULSE, with 20+ self-service modules, and the newer Elosity, which claims 2-6 week study setup and adds direct-to-patient shipping. Its Bluefin product adds supply forecasting. Public pages name few randomization methods, and the only named attestation is SOC 2 Type II.
Sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
What to consider
Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Endpoint Clinical RTSM vs Veeva RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category feature
Endpoint Clinical RTSM
Veeva RTSM
Randomization and blindingFeature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Endpoint Clinical RTSM
Supported
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
Direct-to-patient delivery is stated alongside Bluefin supply forecasting.
Veeva RTSM
Supported
Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.
A study-setup timeline and version-tracked changes without interrupting live studies are stated.
Veeva RTSM
Supported
Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.
Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.
Integrations and platformFeature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Endpoint Clinical RTSM
Extended support
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
API-based integrations connect RTSM with EDC, eCOA, eConsent and CTMS.
Veeva RTSM
Supported
Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.
Product-specific study and patient adoption is reported across a stated country count.
Veeva RTSM
Supported
Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.